FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

104 letters match. Newest first.

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Sanrace Biotechnology Co., Ltd.

    FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.

    High risk
  3. TCI Co., Ltd BioCosme PABP BRANCH

    FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.

    High risk
  4. Babikian Healthcare Products CJSC

    FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.

    High risk
  5. VeganicSKN Limited

    FDA warns VeganicSKN over manufacturing rule failures; drug shipped after failing test and high-risk ingredient not identity-tested.

    High risk
  6. H2 BEV, LLC and H2 RENU, INC

    FDA warns H2 BEV and H2 RENU over unregistered acidified hydrogen beverages with unmonitored pasteurization and drug claims.

    High risk
  7. Fresenius Medical Care AG & Co. KGaA

    Fresenius Medical Care's Ogden, Utah plant failed to investigate leaking peritoneal dialysis bags, leading to a 2026 recall.

    High risk
  8. Dabur India Limited

    FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.

    High risk
  9. IDO Pharm Co., Ltd.

    IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.

    High risk
  10. Nature’s Elements, Inc.

    Nature's Elements sold supplement powders with disease claims as unapproved drugs and made them with no required manufacturing records, FDA says.

    High risk
  11. Patcos Cosmetics Pvt. Ltd.

    Patcos Cosmetics, an Indian OTC drug manufacturer, was cited for insanitary conditions and CGMP violations after a 2025 FDA inspection.

    High risk
  12. Exactech, Inc. dba Advita Ortho

    FDA warned Exactech/Advita Ortho over quality-system failures in Equinoxe shoulder implants found during a July 2025 Sarasota inspection.

    High risk
  13. Bio-Medical Pharmaceutical Manufacturing Corporation

    Bio-Medical Pharmaceutical Manufacturing, a Houston contract manufacturer, was cited for sterile OTC drug current good manufacturing practice (CGMP) failures and drug listing violations.

    High risk
  14. HTO Nevada, Inc. dba Kirkman

    HTO Nevada dba Kirkman, an OTC drug contract manufacturer, was cited for CGMP violations including mislabeled reformulated drugs.

    High risk
  15. Christopher Dale Butler

    FDA warned Christopher Dale Butler that his pickled quail egg products lacked required acidified-food process controls and were deemed adulterated (unsafe under the law).

    High risk
  16. Guangdong Renhe Guozhuang Biotechnology Co., Ltd.

    FDA warns Guangdong Renhe Guozhuang Biotechnology over CGMP failures in OTC drug manufacturing.

    High risk
  17. Medinatura New Mexico, Inc.

    FDA cited Medinatura New Mexico for drug manufacturing rule violations, including weak component testing and cleaning.

    High risk
  18. 3D Imaging Drug Design and Development LLC

    FDA warns 3D Imaging of CGMP failures in sterile PET drug manufacturing and outdated drug listings.

    High risk
  19. PQ Pharmacy, LLC

    FDA warns PQ Pharmacy, a Florida sterile drug compounder, that its products were made under unsafe conditions.

    High risk
  20. Taizhou Kangping Medical Science and Technology Co., Ltd.

    FDA warns Taizhou Kangping about over-the-counter drugs labeled sterile that were not sterilized.

    High risk
  21. Acme United Corporation

    Acme United Corporation made antiseptic wipes with contaminated water and released sterile drugs without sterility testing.

    High risk
  22. Foshan Yiying Hygiene Products Co., Ltd.

    Foshan Yiying, a Chinese OTC drug maker, lacked finished-product testing, stability data and process validation; FDA has blocked its imports.

    High risk
  23. Health and Natural Beauty USA Corp.

    FDA warns Health and Natural Beauty USA over CGMP failures and unapproved, misbranded SprinJene OTC toothpastes, including children’s products.

    High risk
  24. Everlaan Organics, Inc. dba Maple Organics

    FDA warns Maple Organics over OTC drug CGMP failures, unapproved new drugs, and misbranding.

    High risk
  25. Oasis Medical, Inc.

    FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.

    High risk
  26. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  27. Medical Chemical Corporation

    FDA warned Medical Chemical Corp over manufacturing violations, unapproved Tincture Green Soap, and improper drug listing.

    High risk
  28. Exela Pharma Sciences, LLC

    Exela Pharma Sciences failed CGMP (current good manufacturing practice) for sterile injectable drugs, including invalidated sterility-media tests and inaccurate microbiology records.

    High risk
  29. Healwell Homeo Private Limited

    FDA warns Healwell Homeo over pest-infested drug storage and manufacturing violations.

    High risk
  30. Staska Pharmaceuticals, Inc.

    FDA warns Staska Pharmaceuticals, a Nebraska outsourcing facility, that sterile compounded drugs had contamination risks and labeling problems.

    High risk
  31. Zhejiang Huahai Pharmaceutical Co., Ltd.

    FDA warns Zhejiang Huahai Pharmaceutical over CGMP violations including dirty equipment, aseptic-area tape, and data integrity issues.

    High risk
  32. CTK OTC Laboratories LLC formerly FMK LABS, Inc.

    CTK OTC Laboratories, formerly FMK Labs, failed to investigate out-of-spec results and validate processes for OTC drugs, including sunscreens.

    High risk
  33. Zhejiang Easyclean Daily Chemical Co., Ltd

    FDA warned Zhejiang Easyclean Daily Chemical that its OTC drugs lacked required testing and manufacturing controls.

    High risk
  34. Baldwin Richardson Foods Pennsauken, LLC

    FDA warned Baldwin Richardson Foods Pennsauken of serious low-acid canned food violations after finding microbial growth and process-control failures in aseptic non-dairy beverages.

    High risk
  35. Chongqing Tianrun Food Development Co., Ltd

    Chongqing Tianrun Food Development shipped low-acid canned tofu to the U.S. without required canning registration and filed processes.

    High risk
  36. Shantou S.E.Z. Baojie Industry Co., Ltd.

    FDA warns Shantou S.E.Z. Baojie Industry over inadequate CGMP and component testing for OTC drug products, leading to Import Alert 66-40.

    High risk
  37. Empower Clinic Services, LLC dba Empower Pharma

    FDA warns Empower Pharma over sterile drug manufacturing deficiencies, labeling, and unapproved compounded drugs after August 2024 inspection.

    High risk
  38. Neva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi

    FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.

    High risk
  39. Marshalls Traditional Healthcare CC

    Marshalls Traditional Healthcare, an OTC drug maker in South Africa, lacked finished-product release testing and process validation.

    High risk
  40. AmWiner & Raphe Holdings, LLC dba rapheGenerics Corp

    FDA cited rapheGenerics for manufacturing-quality failures and unapproved minoxidil hair regrowth drugs.

    High risk
  41. Miyajima Shoyu Co., Ltd.

    Miyajima Shoyu lacked FDA-filed scheduled processes for acidified Wasabi Dressing, making it adulterated.

    High risk
  42. Phillips Precision, Inc.

    FDA says Phillips Precision, a contract maker of orthopedic implants and instruments, violated device quality rules for cleaning and process controls.

    High risk
  43. Mid America Pet Food LLC

    FDA warned Mid America Pet Food after Salmonella-linked recalls and found persistent contamination and animal-food safety-rule violations at its Texas plant.

    High risk
  44. Tova Industries, LLC

    Tova Industries was cited for missing required heat-and-acidity process controls and filings for acidified pancake syrups, vanilla flavorings, and soy sauces.

    High risk
  45. Agustson A/S

    Agustson A/S exported acidified seaweed caviar to the US without following filed scheduled processes and process controls.

    High risk
  46. Advance Nature Sdn Bhd

    FDA warns Malaysia's Advance Nature over inadequate heat-process controls for exported low-acid bamnut milk.

    High risk
  47. MedOffice Saglik Endustri Anonim Sirketi

    FDA warned MedOffice Saglik after an inspection found missing batch release testing and inadequate process validation for over-the-counter drugs.

    High risk
  48. Little Moon Essentials, LLC

    FDA warns Little Moon Essentials over CGMP failures and unapproved topical analgesic drugs made in Dania Beach, Florida.

    High risk
  49. Clean Solutions LLC

    FDA warned Clean Solutions LLC that its OTC hand soaps and sanitizer were adulterated because it released drugs without component or finished-product testing.

    High risk
  50. Brewing Market Coffee

    FDA warns Brewing Market Coffee that its acidified chai teas are adulterated because required scheduled processes and acidified-food controls were missing.

    High risk